Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Skuldtech Identifies New Predictive Markers for Pancreatic Cancer Survival

Published: Thursday, January 31, 2013
Last Updated: Wednesday, January 30, 2013
Bookmark and Share
The companion diagnostic developed by Skuldtech from these biomarkers will make it possible to identify patients most likely to benefit from this new treatment.

Skuldtech has announced that it has successfully used its technological platform to identify new biomarkers during a phase III clinical trial. This discovery made it possible to file a marketing authorization application with the regulatory authorities.

These survival markers were identified during a clinical study, whose purpose was to evaluate the therapeutic efficiency of a new treatment combining AB Science's masitinib and gemcitabine, compared to the current standard pancreatic cancer treatment of gemcitabine only.

Patents have been filed to protect the markers, which are also associated with the masitinib marketing authorization application already filed with regulatory authorities by AB Science.

Based on its technological approach associating gene sequencing with its proprietary bioinformatic tools and gene profiling studies (transcriptome) on blood samples, Skuldtech has identified several sets of blood biomarkers associated with the different groups of patients treated in this phase III clinical trial.

To reach this objective, the first part of the protocol was to collect a blood sample from each patient before treatment, establish its transcriptome and associate it with the patient's clinical progress.

Then significant bioinformatic and biostatistical processing enabled the isolation of biological markers associated with each patient group, with patients grouped according to their overall survival.

These biomarkers will be used for developing future diagnostics that will help choose the treatment and establish clinical prognostics for patients.

"To the best of our knowledge, this is the first time that new biological markers have been discovered during a phase III clinical trial. These markers are both specific to the drug being developed and associated with positive patient response," said Didier Ritter, CEO, Skuldtech.

"This research confirms the quality of our technological approach based on transcriptome analysis performed by gene sequencing combined with our proprietary bioinformatic tools and our genomic-level knowledge of blood," said David Piquemal, scientific director at Skuldtech. "This will make our technology highly attractive for pharmaceutical companies interested in seeing their phase III clinical trials succeed."

Based on the same technological approach, Skuldtech also filed two new patents in 2012.

The first, filed in February, is related to predictive blood markers for four-year survival in patients with Chronic Myelomonocytic Leukemia (CMML).

The second, filed in September, is related to predictive blood markers for an inflammatory joint disease.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Genetics Control Regenerative Properties Of Stem Cells
Researchers define how genetic factors control regenerative properties of blood-forming stem cells.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Gene Editing Yields Tomatoes That Ripen Weeks Earlier
Research team develop method to make tomato plants flower and ripen fruit two weeks faster than current growth rates.
Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Unexpected Role for Epigenetic Enzymes in Cancer
Researchers use epigenetics to identify the role of an enzyme family as regulators of genetic message interpretation in yeast.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!